Literature DB >> 10063429

Relationship between serum C3 levels and traditional risk factors for myocardial infarction.

A Muscari1, G Massarelli, L Bastagli, G Poggiopollini, V Tomassetti, U Volta, G M Puddu, P Puddu.   

Abstract

OBJECTIVE: Serum C3, a complement component produced by macrophages, the liver and the adipose tissue, is associated with the risk of myocardial infarction in men. This study was performed to ascertain the relationships between serum C3 and traditional risk factors in an unselected population sample. METHODS AND
RESULTS: A random population of 1,068 subjects (537 men and 531 women, 23 to 90 years old) was examined for risk factor assessment. Serum C3 was measured by nephelometry. C3 was independently associated with body mass index (P < 0.0005, especially in women), LDL-cholesterol (P = 0.0014 in men and 0.0215 in women), systolic blood pressure (P < 0.05) and, in women, with triglycerides (P = 0.0133) and blood glucose (P = 0.0383), as assessed by multivariate analysis (multiple linear regression). The overall R2 were 0.07 and 0.21 for men and women, respectively. Women over 50 years of age had significantly higher C3 levels, LDL-cholesterol and body mass index than younger women. The correlation of C3 with LDL-cholesterol was present after the age of 40 in men, and 2 decades later in women.
CONCLUSIONS: These data show that serum C3 correlates with a cluster of conventional risk factors for myocardial infarction resembling insulin resistance. Such correlations may be either independent of, or mediated by the development of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10063429

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  13 in total

1.  Effect of hormone replacement therapy on serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels in post-menopausal women.

Authors:  Yi Liu; Liqun LV
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-02

2.  Menopause, complement, and hemostatic markers in women at midlife: the Study of Women's Health Across the Nation.

Authors:  Samar R El Khoudary; Kelly J Shields; Hsiang-Yu Chen; Karen A Matthews
Journal:  Atherosclerosis       Date:  2013-09-05       Impact factor: 5.162

Review 3.  The immune system and hypertension.

Authors:  Madhu V Singh; Mark W Chapleau; Sailesh C Harwani; Francois M Abboud
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 4.  Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis.

Authors:  Antonie J H H M van Oostrom; Jeroen van Wijk; Manuel Castro Cabezas
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  CD59 or C3 are not requred for angiotensin II-dependent hypertension or hypertrophy in mice.

Authors:  Barbara Coles; Ruth Lewis; Peter B Anning; Jonathan Morton; Sivasankar Baalasubramanian; B Paul Morgan; Valerie B O'Donnell
Journal:  Immunology       Date:  2007-04-13       Impact factor: 7.397

6.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

7.  Complement proteins and arterial calcification in middle aged women: Cross-sectional effect of cardiovascular fat. The SWAN Cardiovascular Fat Ancillary Study.

Authors:  Nayana Nagaraj; Karen A Matthews; Kelly J Shields; Emma Barinas-Mitchell; Matthew J Budoff; Samar R El Khoudary
Journal:  Atherosclerosis       Date:  2015-10-24       Impact factor: 5.162

8.  Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease.

Authors:  Jin Hui Tang; Yu Wen; Fei Wu; Xiao Y Zhao; Mei X Zhang; Jie Mi; Katherine Cianflone
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects.

Authors:  Haiying Yu; Yan Yang; Muxun Zhang; Huiling Lu; Jianhua Zhang; Hongwei Wang; Katherine Cianflone
Journal:  Nutr Metab (Lond)       Date:  2006-02-10       Impact factor: 4.169

10.  Polymorphism of C3 complement in association with myocardial infarction in a sample of central Tunisia.

Authors:  Nadia Leban; Karim Jraba; Abdelkader Chalghoum; Selma Hassine; Donia Elhayek; Sabri Denden; Ramzi Lakhdhar; Faouzi Maatoug; Habib Gamra; Hammadi Braham; Jemni Ben Chibani; Amel Haj Khelil
Journal:  Diagn Pathol       Date:  2013-06-13       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.